Functional assays demonstrated that ARL4C knockdown sensitized CRC cells to oxaliplatin and promoted apoptosis, whereas ARL4C overexpression accelerated tumor growth and impaired chemotherapy response in vivo. This evidence concerns the gene ARL4C and colorectal carcinoma.